Actively Recruiting

Phase 1
Age: 18Years +
All Genders
Healthy Volunteers
NCT07219940

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

Led by Shine-On Biomedical Co., Ltd. · Updated on 2026-01-26

15

Participants Needed

1

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.

CONDITIONS

Official Title

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  1. Male or female subjects aged ≥ 18 years old
  2. Overtly healthy subject, who is considered to be generally healthy based on medical history, 12-lead ECG, and physical examinations, as judged by the Investigator
  3. Able to understand and comply with procedures in the protocol as judged by Investigator and sign the informed consent form (ICF)
  4. Adequate organ function
Not Eligible

You will not qualify if you...

  1. With known or suspected to be hypersensitivity to HLA-G related treatment.
  2. Confirmed active HIV, HBV, or HCV infection
  3. With active fungal, bacterial, viral or atypical infection requiring systemic medication
  4. History of cancer (malignancy) or have ever received any anti-cancer therapy
  5. Has ever received cell therapy or organ transplantation
  6. Substance abuse or addictive use of drugs for nonmedical purposes
  7. Female subject is lactating, has a positive pregnancy test or refuse to practice highly effective contraception
  8. Male subjects with a female spouse/partner who is of childbearing potential refuse to adopt at least one highly effective method of contraception

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Parexel International - Baltimore Early Phase Clinical Unit

Baltimore, Maryland, United States, 21225

Actively Recruiting

Loading map...

Research Team

J

Jennifer Ho

CONTACT

O

Oscar Yang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here